Tirvalimogene teraplasmid

N/A

Report date: 2026/03/27 20:01:50

Base Information

Drug NameTirvalimogene teraplasmid
Drug Alias NamepGX27E6E7GX-188EGX-188
ClassificationVaccines > Development/production technology > Nucleic acid vaccine > DNA vaccineVaccines > Application > Therapeutic vaccine
Mechanisms of ActionImmunostimulants
TargetsNot applicable
Therapy Area/IndicationsUterine Cervical NeoplasmsSquamous Cell Carcinoma of Head and NeckCervical Intraepithelial Neoplasia
Global Approved IndicationsN/A
Approved Indications in ChinaN/A
Original Approved Country/TerritoryN/A
Original Approved DateN/A
Country/TerritoryUkraineSouth KoreaEstonia
CombinationsNo
Global Highest StatusPhase 2 Clinical
Highest Status in ChinaN/A
Originator CompaniesGannex Pharma Co Ltd
China Registration ClassN/A

Develop Information

Inactive CompaniesN/A
Active IndicationsUterine Cervical NeoplasmsSquamous Cell Carcinoma of Head and Neck
Inactive IndicationsCervical Intraepithelial Neoplasia

Other Information

ATC CodeN/A
Related LinksN/A